Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor

Launched by BAKER HEART AND DIABETES INSTITUTE · Oct 11, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to care for patients who have both heart failure and cognitive impairment, which means they might have trouble thinking clearly or remembering things. The goal of the study is to see if this new care model can help improve brain function, lower the risk of developing dementia, and reduce heart problems. The program will use advanced digital tools to help make this new approach work across many healthcare settings.

To be eligible for this trial, participants need to have been hospitalized for heart failure and show at least mild cognitive impairment when they leave the hospital. It's important that they can give consent and are not part of another clinical trial. Once enrolled, participants can expect to receive specialized care aimed at improving both their heart health and cognitive abilities over the next year. This study could change how we care for patients with these conditions and help prevent further decline in their mental health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Hospitalised with HF as primary or secondary diagnosis.
• • 2. At least mild cognitive impairment (CI) based on Montreal Cognitive Assessment (MoCA) on hospital discharge.
• Exclusion Criteria:
• • 1. Unable to provide written consent; requiring palliative care; or participating in another RCT
• • 2. Recovery of cognitive function shortly after hospital discharge: to ensure that we only include patients with "true" CI, any patients with a repeated MoCA\>25 at 2 weeks post-discharge will be excluded.
• • 3. Terminal illness (eg. cancer) that may influence 12-month prognosis.